Y Intercept Hong Kong Ltd decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 27.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,338 shares of the biotechnology company’s stock after selling 29,627 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioMarin Pharmaceutical were worth $4,425,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Norges Bank acquired a new position in BioMarin Pharmaceutical in the fourth quarter valued at $447,572,000. Vestal Point Capital LP raised its holdings in BioMarin Pharmaceutical by 261.4% in the fourth quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after buying an additional 2,170,000 shares during the period. Capital Research Global Investors raised its holdings in BioMarin Pharmaceutical by 547.5% in the third quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after buying an additional 2,145,717 shares during the period. Viking Global Investors LP grew its stake in BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after buying an additional 1,488,552 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of BioMarin Pharmaceutical by 48.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after acquiring an additional 1,076,568 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.
BioMarin Pharmaceutical Stock Performance
Shares of BMRN stock opened at $58.99 on Monday. The stock has a market capitalization of $11.40 billion, a price-to-earnings ratio of 43.06, a PEG ratio of 0.45 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $66.28. The company’s 50-day simple moving average is $54.80 and its 200-day simple moving average is $56.71. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81.
Insider Activity at BioMarin Pharmaceutical
Analyst Ratings Changes
Several equities analysts recently weighed in on BMRN shares. Weiss Ratings upgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, June 26th. Morgan Stanley decreased their price target on BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Jefferies Financial Group reiterated a “buy” rating and set a $103.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. The Goldman Sachs Group assumed coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 target price on the stock. Finally, Sanford C. Bernstein lowered their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.67.
Check Out Our Latest Analysis on BMRN
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Featured Articles
- Five stocks we like better than BioMarin Pharmaceutical
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
